ʻO Trazhenta kahi lāʻau lapaʻau hypoglycemic no ka hoʻohana kūloko. Loaʻa ka lāʻau lapaʻau i ke ʻano o nā ʻulaʻula kukui, nā ʻāpana hāwele. Loaʻa i ka papa kuhikuhi i nā ʻaoʻao convex a me nā kihi beveled. Ua hōʻailona ʻia ka hōʻailona o ka mea hana ma kekahi ʻaoʻao, a i hoʻopaʻa ʻia ka hōʻailona ʻo "D5" ma kekahi.
ʻ saylelo nā ʻōlelo i ka ʻāpana nui o kēlā me kēia pā o Trazhenta ka linagliptin, aia ka nui o 5 mg. Nā mea hou aku:
- 2.7 mg magnesium stearate.
- 18 mg kāpala pregelatinized.
- 130.9 mg o ka mannitol.
- 5.4 mg o ka copovidone.
- 18 mg starch mais.
- ʻO ka hoʻonohonohoʻana o kahi kinikini nani e komo pū ai i kahi māpeka ʻulaʻula (02F34337) 5 mg.
Hoʻopili ʻia ka lāʻau lapaʻau o Trazent i nā palani alumini, 7 mau papa i kēlā ʻO nā māka, ma ka ʻaoʻao, aia i loko o nā pahu kāleka o 2, 4 a i ʻole 8 mau ʻāpana. Inā hoʻopaʻa ka ʻula i nā papa he 10, a laila ma loko o hoʻokahi pahu i ka 3 mau ʻāpana.
ʻO ka hana lāʻau lapaʻau ma ka lāʻau
ʻO ka mea hana nui o ka lāʻau lapaʻau ka mea hōʻili o ka enzyme dipeptidyl peptidase-4 (DPP-4). He hopena ʻino kēia mea i nā hormone infletin (GLP-1 a me GUI), pono no ke kino kanaka e mālama pono i nā pae kō.
Ma hope koke o ka ʻai ʻana i ke kino, ke ʻano o ka ʻai ʻana o nā lua e hiki ai. Inā maʻamau a pae iki paha ka pae o ka glucose koko, hoʻomehana kēia mau hormones i ka hana o ka insulin a me kāna nīna e ka parenchyma. ʻO ka hormone GLP-1, kahi hoʻohui, e hōʻemi ana i ka hana o ka glucose e ka pepi.
Hoʻololi koke i ka lāʻau lapaʻau ponoʻī a me nā mea hoʻohālike e hoʻonui i ka helu o ka incretins e ko lākou nohoʻana a me ka hana e pili ana iā lākou, e hāʻawi i kā lākou hana lōʻihi.
Ma nā loiloi o Trazhent, hiki i kekahi ke ʻike i nā ʻōlelo e hoʻonāukiuki i ka lāʻau lapaʻau i ka hoʻonui ʻana i ka hana o ka glucose e hilinaʻi ai i ka insulin a me ka hōʻemi ʻana i ka hana o glucagon. Ma muli o kēia, ua hoʻāla pono ka nui o ka glucose koko.
Nā hōʻike no ka hoʻohana ʻana a me ke kuhikuhi ʻana
Hāʻawi ʻia ka trazent no ka hoʻohana ʻana i nā maʻi i loaʻa i ka maʻi diabetes 2 ʻano, i ka hoʻohui aʻe:
- ʻO kēia wale nō ka lāʻau maikaʻi loa no nā poʻe maʻi me ka loaʻa ʻole o ka mau glycemic control, hiki ke hele mai ma muli o ka hana pilikino a me ka meaʻai.
- Hoike ʻia kekahi trazent i ka wā i loaʻa ʻole ai ka maʻi papaha, kahi i pāpā ʻia ai ka metformin e lawe a loaʻa ʻole kahi intolerance e hui ai i ka metformin e ke kino.
- Hiki ke hoʻohana i ka trazent i ka hui pū me thiazolidinedione, nā derivatives o ka sulfonylurea, me ka metformin. A i ʻole, i ka wā me ke kau ʻana o kēia mau lāʻau, nā haʻuki, ka mālama ʻana i ka meaʻai ʻana, ʻaʻole i lawe i ka hopena kūpono.
Nā maʻi hoʻohālikelike i ka hoʻohana ʻia ʻana o ka lāʻau lapaʻau
Ua hōʻike maopopo ʻia ka hōʻike ʻana i ka lāʻau lapaʻau ʻaʻole ʻae ʻia ʻo Trazhenta no ka hoʻohana ʻana:
- i ka wā hāpai;
- me ka maʻi ʻōpala 1;
- i ka wā lactation;
- mai kuhikuhi i ka lāʻau lapaʻau i nā keiki ma lalo o 18 makahiki o kona mau makahiki;
- nā mea e hypersensitive i kekahi mau ʻāpana o Trazhenta;
- nā poʻe me ka ketoacidosis i kumu o ka maʻi maʻi.
Ke ʻano o ka noi
ʻO ka ʻōmole i ʻōlelo ʻia no nā maʻi pākeke he 5 mg, pono e lawe ʻia ka lāʻau i nā manawa 3 i ka lā, e kuhikuhi pono ana nā ʻōkuhi. Inā lawe ʻia ka lāʻau e hui pū me ka metformin, a laila ʻaʻole i loli ka hopena o nā hopena.
A trazent no nā maʻi me ka hana renal impaired i ʻole e koi i kekahi hoʻoponopono hoʻoponopono.
Kūleʻa nā haʻawina ʻo Pharmacokinetic e koi paha ʻo Trazent i ka hoʻoponopono hoʻoponopono ʻia no ka hiki ʻana o nā ate. Eia nō naʻe, ua nele ka ʻike me ka hoʻohana ʻana i ka lāʻau lapaʻau e nā mea maʻi like.
ʻAʻole pono kēia hoʻoponopono kūpono no nā mea maʻi maʻi. Akā no kahi pūʻulu o nā kānaka ma hope o 80 makahiki, ʻaʻole koʻikoʻi nā kauka e lawe i ka lāʻau lapaʻau, no ka mea ʻaʻohe ʻike o ka hoʻohana ʻana i nā lāʻau lapaʻau i kēia makahiki.
Pehea nā palekana o Trazenta no nā keiki a me nā wā ʻōpio.
Inā paʻa kahi maʻi i ka lawe mau ʻana i kēia lāʻau lapaʻau no kekahi kumu i ka hala, a laila hoʻihoʻi koke ʻia ka papa me ka manawa hiki. Akā, mai pāpālua i ka nui. Hiki iā ʻoe ke lawe i ka lāʻau lapaʻau i kēlā me kēia manawa, me ka ʻole o ka meaʻai.
He aha kahi hanana o ka lāʻau lapaʻau e alakaʻi ai?
Wahi a nā noiʻi olakino (he mea i kono ʻia nā mea maʻi e noiʻi ʻia), he mea maopopo no ka loaʻa ʻana o kahi lāʻau lapaʻau i ka nui o nā papa 120 (600 mg) ʻaʻole i hōʻino i ke olakino o kēia mau kānaka.
I kēia mau lā, ʻaʻohe palapala o ka overdose me kēia lāʻau lapaʻau i hoʻopaʻa ʻia. ʻOiaʻiʻo, inā lawe nui kahi kanaka i Trazhenta, pono ia e kāpae koke i nā mea o loko o kona ʻōpū, me ka hoʻomau ʻana a me ka loʻi. Ma hope o kēlā, ʻaʻole ia e hōʻeha e nīnau aku i ke kauka.
He mea hiki ke ʻike ka loea i kekahi mau ʻāʻī a kuhikuhi i ka mālama kūpono.
Lilo i ka lāʻau lapaʻau i ka wā hāpai a me ka lactation
ʻO ka hoʻohana ʻana o Trazenti e nā wahine i ka wā hānau o ke keiki, ʻaʻole nō i aʻo ʻia. Eia naʻe, noiʻi nā holoholona no ka lāʻau lapaʻau ʻaʻohe hōʻailona o ka pumehana o ka reproduction. ʻOiai ʻo kēia, i ka wā hāpai, hāʻawi nā kauka e pale i ka hoʻohana ʻana i ka lāʻau.
ʻO nā ʻikepili i loaʻa ma muli o ka loiloi a ka pharmacodynamic i ka holoholona e hōʻike i ka waiwai o ka linagliptin a i ʻole nā mea i loko o ka waiū o ka wahine hānai.
No laila, ʻaʻole i haʻalele ʻia ka hopena o ka lāʻau i nā keiki hou i ʻōpiopio.
I kekahi mau hihia, makemake paha nā kauka e hoʻokuʻu i ka hōʻeha umauma inā makemake ke ʻano o ka makuahine i ka lawe ʻana iā Trazenti. ʻAʻole hana ʻia nā haʻawina o ka hopena o ka lāʻau i ke kanaka hiki ke hānō. ʻAʻole loaʻa nā hoʻokolohua i nā holoholona ma kēia wahi i ka hopena maikaʻi ʻole; ʻo ka loiloi ʻana e nā ʻepekema hoʻi i hōʻoia ʻole i ka pōʻino o ka lāʻau.
Nā hopena hopena
ʻO ka nui o nā hopena ʻaoʻao ma hope o ka lawe ʻana iā Trazhenta ua like like me ka helu o nā hopena maikaʻi ʻole ma hope o ka lawe ʻana i kahi placebo.
Eia ka hopena i hiki ke kiʻi ma hope o ka lawe ʻana iā Trazhenty:
- lōkohu
- ua mai
- nasopharyngitis (kahi maʻi maʻi pāpaʻi);
- hypertriglyceridemia;
- ka hoʻāʻo ʻana i kekahi mau mea o ka lāʻau lapaʻau.
Nui! Hiki i nā Compzents Trazenti ke hoʻohālikelike. No laila, ma hope o ka lawe ʻana i ka lāʻau, ʻaʻole ikaika e ʻimi i ke kaʻa.
ʻO nā hopena ʻaoʻao ma luna e haua pono me ka hui pū ʻana o ka hoʻohana ʻana o Trazhenta a me nā mea hoʻohālikelike me ka metformin a me nā derivatives sulfonylurea.
ʻO ka lawelawe pū ʻana o ka pioglitazone a me ka linagliptin pono e hoʻopili i ka hoʻonui ʻana i ke kaupaona kino, ka ulu ʻana o ka pancreatitis, hyperlipidemia, nasopharyngitis, pūlohi, a ma kekahi mau mea maʻi me ka hypersensitivity mai ka ʻōnaehana.
Me ka hoʻohana pū ʻana o ka lāʻau me ka metformin a me nā derivatives o ka sulfonylurea, hypoglycemia i ka wā o ka hapai, ka mare, pancreatitis, nasopharyngitis a me ka hypersensitivity i nā mea o ka lāʻau hiki ke kū mai.
ʻO ke ola a me nā ʻōlelo pono
ʻO nā ʻōlelo a ka hoʻopiʻi ʻana me ka lāʻau lapaʻau e ʻōlelo pono ʻoe e mālama i kēia lāʻau lapaʻau i ka mahana o ka mea ʻole e kiʻekiʻe aʻe ma mua o 25 mau degere a ke i kahi pōʻeleʻele ʻole i hiki i nā keiki. ʻO 2 mau makahiki kau ka palena o Trazenti.
ʻAʻole kākau nā kauka iā Trazent i nā poʻe me ka maʻi ketoacidosis maʻi. ʻAʻole ʻae ʻia ka lāʻau lapaʻau no ka maʻi maʻi type 1. ʻO ka hopena o ka hoʻomohala ʻana i ka hypoglycemia i ka wā e lawe ai iā Trazhenta e like me ia e hiki ai i ka wā e hoʻohana ai i kahi pletebo.
Hiki i nā hua o nā sulfonylureas ke hoʻonāukiuki i ka hypoglycemia, no laila, pono ke hui pū ʻia kēia mau lāʻau lapaʻau me ka linagliptin me ka nui loa. Inā pono, hiki i ka endocrinologist ke hōʻemi i ka nui o nā derivatives o ka sulfonylurea.
I kēia lā, ʻaʻohe mau o ka ikepili hilinaʻi no ka noiʻi olakino e haʻi aku i ka pili o Trazhenta me ka hormone-insulin. No ka poʻe e ʻeha ana me ka maikaʻi ʻole o ka pāpā, i kuhikuhi ʻia i ka lāʻau me ke ʻano o nā lāʻau hypoglycemic ʻē aʻe, a e hoʻomau ʻia ka loiloi.
ʻOi ka hoʻokaʻina o ke kō i loko o ke kahe koko e hoʻemi ʻia loa i ka wā e lawe ai ka mea maʻi iā Trazhenta a i ʻole nā lāʻau like ʻole ma mua o ka papaʻaina.
